摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2-Dimethyl-4-isopropyl-imidazol | 32016-43-6

中文名称
——
中文别名
——
英文名称
1,2-Dimethyl-4-isopropyl-imidazol
英文别名
4-Isopropyl-1,2-dimethyl-imidazol;4-isopropyl-1,2-dimethyl-1H-imidazole;1,2-Dimethyl-4-propan-2-ylimidazole
1,2-Dimethyl-4-isopropyl-imidazol化学式
CAS
32016-43-6
化学式
C8H14N2
mdl
——
分子量
138.213
InChiKey
STXDYRJLVDLSKM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    17.8
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS
    申请人:Merck Patent GmbH
    公开号:US20160016951A1
    公开(公告)日:2016-01-21
    The present invention relates to naphthyridine and isoquinoline compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of CDK8/19, and for the treatment of CDK8/19-related disorders.
    本发明涉及啶和异喹啉化合物,以及由此组成的药物可接受的组合物,作为CDK8/19的抑制剂,用于治疗与CDK8/19相关疾病。
  • PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
    申请人:Huang Taisheng
    公开号:US20110224190A1
    公开(公告)日:2011-09-15
    The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    本发明提供了哌啶-4-基氮杂环丙烷生物,以及它们的组合物和使用方法,这些衍生物调节Janus激酶1(JAK1)的活性,并且在治疗与JAK1活性相关的疾病方面具有用处,例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
  • RAS INHIBITORS
    申请人:Revolution Medicines, Inc.
    公开号:US20210130369A1
    公开(公告)日:2021-05-06
    The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    该披露涉及大环化合物,以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物,以及它们在治疗癌症中的用途。
  • SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES
    申请人:Bayer Aktiengesellschaft
    公开号:US20200390100A1
    公开(公告)日:2020-12-17
    The present invention relates to substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants.
    本发明涉及通式(I)或其盐的取代N-杂环烷基和N-杂芳基四氢嘧啶酮,其中通式(I)中的基团对应于描述中给出的定义,并将其用作除草剂,特别是用于控制作物中的阔叶杂草和/或杂草草,并/或作为植物生长调节剂,以影响作物的生长。
  • TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
    申请人:Sun Chongqing
    公开号:US20080194625A1
    公开(公告)日:2008-08-14
    The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.
    本发明提供了式I的化合物,其中取代基如本文所述。还提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统疾病、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的药物组合物以及本发明化合物与其他治疗剂的药物组合物。
查看更多